LOUPAKIS, FOTIOS
 Distribuzione geografica
Continente #
NA - Nord America 1.136
EU - Europa 319
AS - Asia 293
AF - Africa 13
OC - Oceania 12
SA - Sud America 9
Totale 1.782
Nazione #
US - Stati Uniti d'America 1.117
CN - Cina 140
IT - Italia 97
FR - Francia 69
DE - Germania 42
GB - Regno Unito 35
JP - Giappone 35
VN - Vietnam 31
IN - India 22
TW - Taiwan 20
CA - Canada 16
AT - Austria 12
AU - Australia 12
SG - Singapore 12
ID - Indonesia 10
NL - Olanda 10
FI - Finlandia 8
KR - Corea 8
ES - Italia 7
RU - Federazione Russa 7
ZA - Sudafrica 7
CH - Svizzera 6
IE - Irlanda 6
PL - Polonia 6
TR - Turchia 5
DK - Danimarca 4
BR - Brasile 3
CO - Colombia 3
HK - Hong Kong 3
MX - Messico 3
BE - Belgio 2
EG - Egitto 2
LB - Libano 2
MA - Marocco 2
PK - Pakistan 2
AR - Argentina 1
CL - Cile 1
CZ - Repubblica Ceca 1
GR - Grecia 1
IL - Israele 1
JO - Giordania 1
LT - Lituania 1
LV - Lettonia 1
PT - Portogallo 1
RE - Reunion 1
RO - Romania 1
SE - Svezia 1
TH - Thailandia 1
TN - Tunisia 1
UA - Ucraina 1
VE - Venezuela 1
Totale 1.782
Città #
Fairfield 104
Ashburn 94
Buffalo 77
Seattle 73
Houston 72
Santa Cruz 70
Woodbridge 70
Ann Arbor 41
Cambridge 34
Chicago 34
Beijing 30
Serra 27
Wilmington 25
University Park 18
Shanghai 17
Los Angeles 16
Pisa 16
Dong Ket 15
Shenyang 14
Dallas 13
Taipei 12
Des Moines 11
Fiume Veneto 11
Milan 11
Phoenix 11
Vienna 10
Clearwater 9
Las Vegas 9
Paris 9
Muizenberg 7
New York 7
San Francisco 7
Tokyo 7
Allston 6
Bath 6
Boston 6
Bremen 6
Helsinki 6
Rochester 6
Wuhan 6
Dublin 5
Guangzhou 5
Hanoi 5
Ottawa 5
Singapore 5
Suzhou 5
Sydney 5
Taiyuan 5
Toronto 5
Bengaluru 4
Berlin 4
Bristol 4
De Bilt 4
Henderson 4
Herndon 4
Icheon-si 4
Kolkata 4
Lake Forest 4
London 4
Mountain View 4
Nanjing 4
Osaka 4
Providence 4
Provo 4
Salisbury 4
San Jose 4
Tampa 4
Ankara 3
Bellevue 3
Boardman 3
Bogotá 3
Copenhagen 3
Falkenstein 3
Hangzhou 3
Jacksonville 3
Montereale Valcellina 3
Ningbo 3
Pittsburgh 3
Portland 3
Risch 3
San Diego 3
Toulouse 3
Amsterdam 2
Aurangabad 2
Beirut 2
Chelmsford 2
Columbus 2
Crewkerne 2
Duncan 2
Fort Mill 2
Gurgaon 2
Innsbruck 2
Jinan 2
Leeds 2
Louisville 2
Lyon 2
Melbourne 2
Mount Druitt 2
Mumbai 2
Oxford 2
Totale 1.221
Nome #
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: Updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study, file e0d6c930-e9b0-fcf8-e053-d805fe0aa794 288
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer, file e0d6c926-e72d-fcf8-e053-d805fe0aa794 214
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer, file e0d6c92c-3dc5-fcf8-e053-d805fe0aa794 203
Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients, file e0d6c928-e94d-fcf8-e053-d805fe0aa794 162
KRAS status and risk of venous thromboembolic events in patients with metastatic colorectal cancer: a case-control study., file e0d6c927-5065-fcf8-e053-d805fe0aa794 159
Angiogenesis genotyping and clinical outcome during regorafenib treatment in metastatic colorectal cancer patients, file e0d6c928-e8df-fcf8-e053-d805fe0aa794 140
KRAS and BRAF genotyping of synchronous colorectal carcinomas., file e0d6c927-102d-fcf8-e053-d805fe0aa794 131
Prognostic significance of KRAS mutation rate in metastatic colorectal cancer patients., file e0d6c927-5350-fcf8-e053-d805fe0aa794 117
TRIBE-2: A phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group, file e0d6c92c-363a-fcf8-e053-d805fe0aa794 106
Molecular and pathological characterization of the EZH2 rs3757441 single nucleotide polymorphism in colorectal cancer, file e0d6c92b-0288-fcf8-e053-d805fe0aa794 98
Circulating microRNAs in metastatic colorectal cancer (mCRC) patients (pts) treated with regorafenib, file e0d6c927-46be-fcf8-e053-d805fe0aa794 91
Glucose metabolism enzymes gene expression analysis and selective metabolic advantage in the clinical progression of colorectal cancer (CRC), file e0d6c927-4ffc-fcf8-e053-d805fe0aa794 58
DPYD c.1905+1G>A and c.2846 A>T and UGT1A1*28 allelic variants as predictors of toxicity: Pharmacogenetic translational analysis from the phase III TRIBE study in metastatic colorectal cancer., file e0d6c92b-676c-fcf8-e053-d805fe0aa794 17
Folfoxiri in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO)., file e0d6c926-deb9-fcf8-e053-d805fe0aa794 15
DPYD and UGT1A1 genotyping to predict adverse events during first-line FOLFIRI or FOLFOXIRI plus bevacizumab in metastatic colorectal cancer, file e0d6c92a-065f-fcf8-e053-d805fe0aa794 11
Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: Final results of the randomized BEBYP trial, file e0d6c92f-ec8e-fcf8-e053-d805fe0aa794 10
Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers, file e0d6c92a-b1ad-fcf8-e053-d805fe0aa794 5
BRAF-mutated metastatic colorectal cancer between past and future, file e0d6c92c-3ba7-fcf8-e053-d805fe0aa794 5
Primary Tumor Sidedness and Benefit from FOLFOXIRI plus Bevacizumab as Initial Therapy for Metastatic Colorectal Cancer, file e0d6c92f-d335-fcf8-e053-d805fe0aa794 3
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: Updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study, file 1761d038-570a-494e-8068-60f2f66b9017 2
Vinorelbine in BRAF V600E mutated metastatic colorectal cancer: a prospective multicentre phase II clinical study, file e0d6c92c-0d56-fcf8-e053-d805fe0aa794 2
Copy number load predicts outcome of metastatic colorectal cancer patients receiving bevacizumab combination therapy, file e0d6c92c-1a17-fcf8-e053-d805fe0aa794 2
Tandem repeat variation near the HIC1 (hypermethylated in cancer 1) promoter predicts outcome of oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer, file e0d6c92c-2675-fcf8-e053-d805fe0aa794 2
null, file e0d6c92c-2702-fcf8-e053-d805fe0aa794 2
Single-agent panitumumab in frail elderly patients with advanced RAS and BRAF wild-type colorectal cancer: Challenging drug label to light up new hope, file e0d6c92c-3dbf-fcf8-e053-d805fe0aa794 2
null, file e0d6c92c-4816-fcf8-e053-d805fe0aa794 2
Immunogenic cell death pathway polymorphisms for predicting oxaliplatin efficacy in metastatic colorectal cancer, file e0d6c92f-93e6-fcf8-e053-d805fe0aa794 2
Polymorphisms within immune regulatory pathways predict cetuximab efficacy and survival in metastatic colorectal cancer patients, file e0d6c92f-97b9-fcf8-e053-d805fe0aa794 2
Quantitative evidence for early metastatic seeding in colorectal cancer, file e0d6c930-9b09-fcf8-e053-d805fe0aa794 2
null, file e0d6c930-9f05-fcf8-e053-d805fe0aa794 2
null, file e0d6c930-b1b8-fcf8-e053-d805fe0aa794 2
Location of primary tumor and benefit from anti-epidermal growth factorreceptor monoclonalantibodies in patients with RAS and BRAF wild-typemetastatic colorectal cancer, file e0d6c930-c440-fcf8-e053-d805fe0aa794 2
Topoisomerase 1 promoter variants and benefit from irinotecan in metastatic colorectal cancer patients, file e0d6c92b-688f-fcf8-e053-d805fe0aa794 1
NOS2 polymorphisms in prediction of benefit from first-line chemotherapy in metastatic colorectal cancer patients, file e0d6c92c-0f69-fcf8-e053-d805fe0aa794 1
null, file e0d6c92c-2f20-fcf8-e053-d805fe0aa794 1
Totale 1.862
Categoria #
all - tutte 3.573
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 3.573


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201963 0 0 0 0 0 0 0 0 0 0 32 31
2019/2020366 18 15 9 27 50 43 50 47 47 21 16 23
2020/2021322 15 25 2 17 36 33 47 19 39 20 44 25
2021/2022289 26 9 10 33 43 15 16 7 13 8 83 26
2022/2023319 8 17 67 56 18 25 12 38 42 9 15 12
2023/2024402 11 14 28 21 76 53 56 64 20 48 11 0
Totale 1.862